Perceptive Informatics
today unveiled the new release of its DataLabs® Electronic Data Capture (EDC) solution, which provides richer functionality to further streamline the clinical trial process. The
DataLabs 5.0 EDC solution
enables clinical trial sponsors to more efficiently manage the clinical development process from study design to collection and reporting of study data. Unlike other EDC solutions, the DataLabs EDC solution benefits from interoperability with other systems in the Perceptive eClinical Suite to provide real-time data interchange and enable more effective decision making for clinical development programs.
Perceptive offers the DataLabs EDC solution, and other solutions in its eClinical Suite, as a software-as-a-service (SaaS) application, which is hosted, maintained, and supported by Perceptive’s eClinical platform. Newly enhanced features of the DataLabs 5.0 EDC solution, which has a user-friendly interface, include a powerful reporting engine, web-based study design tool, and sophisticated search function, as well as advanced export functionality to extract EDC data.
Perceptive has incorporated convergence into its eClinical Suite, which allows the functionality that exists in one application to be accessed through another. The convergence between the Perceptive DataLabs EDC solution and Randomization and Trial Supply Management (RTSM) technologies allow users to randomize and dispense medication from either system. With new dynamic forms and visit functionality available in the DataLabs 5.0 EDC solution any changes that are made within the RTSM technologies will automatically trigger within the EDC system a dynamic patient visit to occur. This capability supports mid-study protocol amendments commonly required in adaptive trials.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.